LncRNAs play critical roles in various pathophysiological and biological processes, such as protein translation, RNA splicing, and epigenetic modification. Indeed, abundant evidences demonstrated that lncRNA act as competing endogenous RNAs (ceRNAs) to participate in tumorigenesis. However, little is known about the underlying function of lncRNA in nonhomologous end joining (NHEJ) pathway 1 (LINP1) in pediatric and adolescent acute myeloid leukemia (AML). The expression of LINP1 was examined in AML patient samples by qRT‐PCR. Cell proliferation was examined by CCK‐8 and Edu assays. β‐Galactosidase senescence assay, mGlucose uptake assay, lactate production assay, and Gene Ontology (GO) analysis were performed for functional analysis. We found that LINP1 was significantly overexpressed in AML patients at diagnosis, whereas downregulated after complete remission (CR). Furthermore, knockdown of LINP1 expression remarkably suppressed glucose uptake and AML cell maintenance. Mechanistically, LINP1 was found to inhibit the glucose metabolism by suppressing the expression of HNF4a. Both LINP1 and HNF4a knockdown reduced the expression levels of AMPK phosphorylation and WNT5A, indicating for the first time that LINP1 strengthened the HNF4a‐AMPK/WNT5A signaling pathway involved in cell glucose metabolism modulation and AML cell survival. Taken together, our results indicated that LINP1 promotes the malignant phenotype of AML cells and stimulates glucose metabolism, which can be regarded as a potential prognostic marker and therapeutic target for AML.
Objectives: A growing number of studies demonstrate that long noncoding RNAs (lncRNAs) could act as biomarkers to determine the prognosis of acute myeloid leukemia (AML) patients. Nonetheless, the significance of lncRNAs in AML prognosis remains unclear. We conducted a meta-analysis to assess the prognostic indicators of abnormally expressed lncRNAs in AML. Methods: Literature was searched using PubMed, EMBASE, and Web of Science databases up to November 10, 2018. Results: Thirteen studies with 2755 individuals were included. The abnormal expression of lncRNAs was associated with worse overall survival (OS) in AML patients, especially in cytogenetically normal AML (CN-AML), and was associated with shorter disease-free survival and event-free survival. Subgroup analysis showed that high levels of HOTAIR and TUG1 were associated with poor OS. Discussion: Overexpression of lncRNA HOTAIR and TUG1 were reported in two separate studies, and correlated with worse AML prognoses. Conclusion: Abnormally expressed lncRNAs are significantly related to worse prognoses of AML patients and might serve as potential prognostic markers to predict the prognosis of AML patients.
Objective: To assess the correlation of thyroid function and serum immunological indexes in patients with Hashimoto's thyroiditis. Method: To select 172 patients who have been clinically confirmed with HT. And they were divided into Hashimoto hyperthyroidism group within 39 cases, Hashimoto hypothyroidism group within 92 cases and normal Hashimoto's thyroid function group within 41 cases on the basis of Thyroid function. Besides, 50 healthy controls were control group. ECLIA was adopted to test the Thyroid function and antibody indicators of every group, and ELISA was employed to detect Th1 type cytokines (IL-2, IFN-γ) and Th2 type cytokines (IL-6, IL-10). Result: Every group with Hashimoto's thyroiditis was evidently higher than the normal one as well as the Hashimoto hypothyroidism group was higher than the Hashimoto hyperthyroidism group and the normal one in TPOAb and TGAb levels, in which the difference has statistical significance (P<0.05). However, the difference between Hashimoto hyperthyroidism group and Hashimoto hypothyroidism group has no statistical significance (P>0.05); Moreover, the IL-2, IFN-γ levels of the Hashimoto hyperthyroidism group and the normal Hashimoto's thyroid function group were distinctly higher than that of the Hashimoto hypothyroidism group; And the IL-6 and IL-10 levels were obviously higher than the Hashimoto hyperthyroidism group as well as the normal Hashimoto's thyroid function group (P<0.05). Besides, the TSH was positively correlated with the TPOAb and the IL-10. And FT4 was negatively correlated with the TPOAb, TGAb, IL-6. Not only the FT3 and TGAb but also the TT4 and IL-6 were in negative correlation. But the other indexes have no correlation. Conclusion: The patients with Hashimoto's thyroiditis have high TPOAb and TGAb levels. In addition, the TPOAb, TGAb and cytokines levels in the serum of HT patients with different thyroid function have evidently discrepancy, which may be closely related to the occurrence and development of the disease.
The objective is to discuss about the correlation of Glycolipid Metabolism, Cystatin C (CysC) and Homocysteine (Hcy) of thyroid dysfunction. 100 cases of hyperthyroidism, hypothyroidism and the control group are chose respectively to measure Fiber Bragg Grating (FBG), Blood Lipid, Thyroid Hormone (TH), CysC and Hcy, calculate the blood lipid ratio and make analysis. As a result, Thyroid Carcinoma (TC), Thyroglobulin (TG), Low-density Lipoprotein Cholesterol (LDL
Objective: To assess the relationship between thyroid function and T lymphocyte subsets in Patients with Hashimoto's Thyroiditis. Method: To select 131 diagnosed HT patients as the research object, which is divided into HT hyperthyroidism group (Group A) with 18 cases, normal HT thyroid function group (Group B) with 35 cases, HT subclinical hypothyroidism group (Group C) with 42 cases, and HT hypothyroidism group (Group D) with 36 cases in accordance with thyroid function. Besides, 40 cases of healthy check-up people are selected as the control group. ECLIA is adopted to test the thyroid function index of each group, and FCM is adopted to test T lymphocyte subsets. Result: Compare CD3 + T lymphocytes of each group, Group D is obviously higher than Group A, Group B, and the control group, and the difference has statistic significance (P<0.05); Compare CD3 + CD4 + T lymphocyte and CD4 + /CD8 + of each group, Group D is obviously higher than other groups, Group C is obviously higher than Group A, Group B, and the control group, Group A and Group B are obviously higher than the control group, and the differences have statistic significance (P<0.05); Compare CD3 + CD8 + T lymphocytes of each group, Group D is obviously lower than other groups, Group C is obviously lower than Group A, Group B, and the control group, the difference has statistic significance (P<0.05). The correlation analysis shows that TSH is in positive correlation with CD4 + /CD8 + , FT3 is in positive correlation with CD3 + CD8 + T, and FT4 is in positive correlation with CD3 + CD8 + T and in negative correlation with CD4 + /CD8 + . Conclusion: HT patients have the imbalance of T lymphocyte subsets, and the T lymphocyte subsets ratio of HT patients of different thyroid function has obvious differences, which may have close relationship with the occurrence and development of HT.
Object: To investigate the levels of serum interleukin-10 (IL-10) and IL-17 in papillary thyroid carcinoma (PTC) and their relationship with prognosis. Method: 120 PTC patients who underwent radical mastectomy in the Department of Thyroid and Mammary Surgery of Cangzhou Central Hospital from January 2018 to April 2019 were randomly selected as the experimental group, and 120 healthy people who matched 1:1 with the hospital physical examination center in the same period were selected as the control group according to the sex, age and body mass index of the experimental group. Compare the levels of serum IL-10 and IL-17 between the two groups, analyze the relationship between the levels and the pathological features of PTC patients, draw the characteristic curve of subjects' working characteristics, and calculate the area under the curve (AUC) to evaluate the diagnostic value of serum IL-10 and IL-17 for PTC. All patients were followed up for 12 months after operation. Imaging and pathological examination results were used as prognostic indicators. Kaplan-Meier survival analysis was used to analyze the relationship between serum IL-10 and IL-17 levels and the prognosis of PTC patients. COX regression analysis was used to analyze the prognostic factors of PTC patients. Result: The levels of serum IL-10 and IL-17 in experimental group were significantly higher than those in control group (P<0.05). Comparison of serum IL-10 levels in PTC patients with different tumor diameters and lymphatic metastasis showed statistically significant difference (P<0.05). The level of IL-17 in serum of PTC patients with different TNM stages, differentiation degree and lymphatic metastasis was statistically significant (P<0.05). The diagnostic value of serum IL-10 combined with IL-17 in PTC is significantly higher than that of single detection (P<0.05). According to the median serum IL-10 and IL-17 for PTC diagnosis, the postoperative recurrence rate of IL-10 high expression group was significantly higher than that of IL-10 low expression group, and the postoperative recurrence rate of IL-17 high expression group was significantly higher than that of IL-17 low expression group (P<0.05). TNM stage, IL-10 level and IL-17 level are independent risk factors for postoperative recurrence of PTC patients (P<0.05). Conclusion: The elevated levels of serum IL-10 and IL-17 in PTC patients are related to TNM stage, degree of differentiation, maximum tumor diameter and lymphatic metastasis, and are independent risk factors for postoperative recurrence of PTC patients, which may be a reference index for disease diagnosis and prognosis evaluation.
Background: Hashimoto's Thyroiditis is a common autoimmune thyroid disease of organ specificity mediated by T cells, the abnormal activation of auto-reactive T cells has close relation with the attack of HT and participates in the attack process of HT. TPOAb and TGAb is important symbols of HT thyroiditis. Most of patients have continuous TPOAb and TGAb level rise. Objective: To assess the relationship between T Lymphocyte Subsets and TPOAb & TGAb Level in Patients with Hashimoto's Thyroiditis. Method: 130 clinically diagnosed HT patients are selected as the study object and were divided into high level group and low level group (with 65 cases for each group) as per the expression condition of TPOAb and TGAb; another 40 healthy check-up people are selected as the control group. Flow cytometry is adopted to test the T lymphocyte subsets, and ELISA is adopted to test Th1 cytokine (IL-2, IFN-γ) and Th2cytokine (IL-4, IL-10). Result: CD3 + T, CD3 + CD4 + T and CD4 + /CD8 + of high level TPOAb group and high level TGAb group are obviously higher than that of low level group and the control group, CD3 + CD8 + T is obviously lower than that of low level group and the control group; the CD3 + CD4 + T of the low level TPOAb group and low level TGAb group is obviously higher than the control group, which has statistic meaning (P<0.05). IL-2 and IFN-γ of the high level TPOAb group and high level TGAb group is obviously lower than the low level group while higher than the control group, and the IL-4 and IL-10 is obviously higher than the low level group and the control group; the IL-2 and IFN-γ of the low level TPOAb group and low level TGAb is obviously higher than that of high level group and the control group, and the IL-4 and IL-10 is obviously lower than that of the high level group and the control group, and the differences all have statistic meaning (P<0.05). Correlation analysis indicates that TPOAb and TGAb are in positive correlation with CD3 + CD4 + T and CD4 + /CD8 + , while in negative correlation with CD3 + CD8 + T. Conclusion: T lymphocyte subsets in the HT patients have obvious correlation with the level of TPOAb and TGAb, and may have close relationship with the occurrence and development of HT.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.